ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting
March 10 2022 - 5:30AM
Business Wire
Data from Pivotal Trial to be Highlighted in
Oral Presentation on Saturday, March 19
Investor Event to be Held Sunday, March 20 at
7:30 am MST
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that multiple abstracts were selected for oral and
poster presentations at the Society of Gynecologic Oncology (SGO)
Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in
Phoenix, Arizona.
ORAL PRESENTATION Full results from the pivotal SORAYA
trial of mirvetuximab soravtansine (mirvetuximab) in ovarian cancer
will be shared in a late-breaking oral presentation.
Title: Efficacy and Safety of Mirvetuximab Soravtansine in
Patients with Platinum-Resistant Ovarian Cancer with High Folate
Receptor Alpha Expression: Results from the SORAYA Study Presenter:
Dr. Ursula Matulonis, Chief of the Division of Gynecologic Oncology
at the Dana-Farber Cancer Institute, Professor of Medicine at the
Harvard Medical School, and SORAYA Co-Principal Investigator
Session: Scientific Plenary IV: Late-Breaking Abstracts Session
Date: Saturday, March 19, 2022 Session Time: 4:15 pm to 5:45 pm
MST
POSTER PRESENTATIONS Trial in progress posters from
ImmunoGen’s MIRASOL and PICCOLO trials of mirvetuximab in ovarian
cancer and a Phase 2 investigator-sponsored combination trial of
mirvetuximab with carboplatin in the neoadjuvant setting will also
be presented.
Title: MIRASOL: A Randomized, Open-Label, Phase 3 Study of
Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy
in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or
Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Presenter: Dr. Kathleen Moore, Director of the Oklahoma TSET Phase
I Program, Associate Professor of the Section of Gynecologic
Oncology at The University of Oklahoma College of Medicine, and
MIRASOL Principal Investigator
Title: PICCOLO: An Open-Label, Single Arm, Phase 2 Study of
Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive,
High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian
Tube Cancers with High Folate Receptor Alpha Expression Presenter:
Dr. Angeles Alvarez Secord, Professor of Obstetrics and Gynecology
at Duke University School of Medicine in Durham, North Carolina
Title: Single-Arm Phase II Trial of Carboplatin and Mirvetuximab
Soravtansine as Neoadjuvant Chemotherapy for Advanced-Stage
Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate
Receptor α Positive Presenter: Dr. Jhalak Dholakia, Department of
Obstetrics and Gynecology at the University of Alabama
OTHER PRESENTATIONS Final data from the mirvetuximab plus
bevacizumab platinum-agnostic combination study, which were
originally shared at ASCO 2021, will be re-presented.
Title: Mirvetuximab Soravtansine, a Folate Receptor
Alpha-Targeting Antibody Drug Conjugate in Combination with
Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer:
Final Analysis Session: Seminal Abstracts: The Best of ASCO, ESMO,
IGCS, and ESGO Presenter: Dr. David O’Malley, Professor, Director
of Gynecologic Oncology and the Director of the Division of
Gynecologic Oncology at The Ohio State University and the James
Cancer Center
Additional information can be found on the SGO website.
INVESTOR EVENT INFORMATION
ImmunoGen will hold an investor event to discuss the SORAYA
data, featuring a roundtable with key opinion leaders, on Sunday,
March 20 at 7:30 am MST/10:30 am EDT in the Moly Meeting Room at
the Westin Phoenix Downtown. To access the live event by phone,
dial (877) 621-5803; the conference ID is 1986619. The event may
also be accessed via webstream on the Investors and Media section
of the Company’s website, www.immunogen.com. Following the call, a
replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These
statements include, but are not limited to, ImmunoGen's
expectations related to: the potential benefits of the Company's
product candidates and the timing and presentation of preclinical
and clinical data on the Company's product candidates. Various
factors could cause ImmunoGen's actual results to differ materially
from those discussed or implied in the forward-looking statements,
and you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to:
the timing and outcome of the Company's preclinical and clinical
development processes; the difficulties inherent in the development
of novel pharmaceuticals, including uncertainties as to the timing,
expense, and results of preclinical studies, clinical trials, and
regulatory processes; the timing and outcome of the Company's
anticipated interactions with regulatory authorities; obtaining,
maintaining, and protecting the Company's intellectual property;
the Company's ability to financially support its product programs;
risks and uncertainties associated with the scale and duration of
the COVID-19 pandemic and the resulting impact on ImmunoGen's
industry and business; and other factors as set forth in the
Company's Annual Report on Form 10-K filed with the Securities and
Exchange Commission on March 1, 2021, and other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220310005106/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O'Konek
781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting Robert
Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024